Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis.
Sodium zirconium cyclosilicate (SZC) is a novel therapeutic agent for hyperkalemia. However, limited reports have described its real-world safety. In this study, we used the Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluate the safety profilet of SZC. This retr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0320585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850261406973165568 |
|---|---|
| author | Yongfei Yu Kaiyu Zhang Jinglin Gao Guoshun Huang Chen Yong Yuan Wei Enchao Zhou |
| author_facet | Yongfei Yu Kaiyu Zhang Jinglin Gao Guoshun Huang Chen Yong Yuan Wei Enchao Zhou |
| author_sort | Yongfei Yu |
| collection | DOAJ |
| description | Sodium zirconium cyclosilicate (SZC) is a novel therapeutic agent for hyperkalemia. However, limited reports have described its real-world safety. In this study, we used the Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluate the safety profilet of SZC. This retrospective analysis involved FAERS data from the third quarter of 2018 to the fourth quarter of 2023. A disproportionality analysis, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical bayesian geometric mean(EBGM), and bayesian confidence propagation neural network (BCPNN), was conducted to quantify the signals of SZC-related adverse events (AEs). Sex subgroup analyses were also conducted. A total of 1,154 SZC-related AE reports were obtained from the FAERS database. SZC-related AEs primarily targeted 21 system organ classes after simultaneously conforming to the four algorithms. The most common AEs included X-ray gastrointestinal tract abnormalities(ROR = 3888.02[1051.8, 14372.15]) and blood potassium abnormal(ROR = 212.53[134.73, 335.26]), consistent with prior findings and clinical trials. Unexpected significant AEs included ileus (ROR = 27.82[14.44, 53.59]), death (ROR = 17.49[15.7, 19.49]) and congestive cardiac failure (ROR = 16.66[10.94, 25.37]). Sex-based differences were observed for AEs. The median onset time of SZC-related AEs was 33 days. This study confirms common AEs of SZC and identifies new ones, highlighting the need for careful monitoring and facilitating its safe use in clinical settings. However, disproportionality analysis cannot formally prove causation and further studies are needed to confirm these associations. |
| format | Article |
| id | doaj-art-5d8c258e46654f2fb863fe89936074bc |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5d8c258e46654f2fb863fe89936074bc2025-08-20T01:55:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01203e032058510.1371/journal.pone.0320585Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis.Yongfei YuKaiyu ZhangJinglin GaoGuoshun HuangChen YongYuan WeiEnchao ZhouSodium zirconium cyclosilicate (SZC) is a novel therapeutic agent for hyperkalemia. However, limited reports have described its real-world safety. In this study, we used the Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluate the safety profilet of SZC. This retrospective analysis involved FAERS data from the third quarter of 2018 to the fourth quarter of 2023. A disproportionality analysis, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical bayesian geometric mean(EBGM), and bayesian confidence propagation neural network (BCPNN), was conducted to quantify the signals of SZC-related adverse events (AEs). Sex subgroup analyses were also conducted. A total of 1,154 SZC-related AE reports were obtained from the FAERS database. SZC-related AEs primarily targeted 21 system organ classes after simultaneously conforming to the four algorithms. The most common AEs included X-ray gastrointestinal tract abnormalities(ROR = 3888.02[1051.8, 14372.15]) and blood potassium abnormal(ROR = 212.53[134.73, 335.26]), consistent with prior findings and clinical trials. Unexpected significant AEs included ileus (ROR = 27.82[14.44, 53.59]), death (ROR = 17.49[15.7, 19.49]) and congestive cardiac failure (ROR = 16.66[10.94, 25.37]). Sex-based differences were observed for AEs. The median onset time of SZC-related AEs was 33 days. This study confirms common AEs of SZC and identifies new ones, highlighting the need for careful monitoring and facilitating its safe use in clinical settings. However, disproportionality analysis cannot formally prove causation and further studies are needed to confirm these associations.https://doi.org/10.1371/journal.pone.0320585 |
| spellingShingle | Yongfei Yu Kaiyu Zhang Jinglin Gao Guoshun Huang Chen Yong Yuan Wei Enchao Zhou Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis. PLoS ONE |
| title | Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis. |
| title_full | Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis. |
| title_fullStr | Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis. |
| title_full_unstemmed | Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis. |
| title_short | Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis. |
| title_sort | safety assessment of sodium zirconium cyclosilicate a faers based disproportionality analysis |
| url | https://doi.org/10.1371/journal.pone.0320585 |
| work_keys_str_mv | AT yongfeiyu safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis AT kaiyuzhang safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis AT jinglingao safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis AT guoshunhuang safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis AT chenyong safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis AT yuanwei safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis AT enchaozhou safetyassessmentofsodiumzirconiumcyclosilicateafaersbaseddisproportionalityanalysis |